Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Additional study for the antibiotic will take 18 months to complete, company says
You may also be interested in...
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.
Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
With the growing problem of antimicrobial resistance putting the spotlight on the need for novel antibiotics, FDA has opened the debate on whether incentives, similar to the orphan drug system, are needed to prompt R&D in the area. But at a recent workshop on the issue, advocacy groups suggested that any such incentives need to be partnered with a more active role on the part of FDA.